Prostate cancer Board decisions

The Board denied the veteran's claims for service connection for CAD, COPD, diabetes mellitus, and prostate cancer, finding that these conditions were not related to his military service or asbestos exposure.

The VA denied the veteran's claim for service connection of prostate cancer, finding that it did not manifest during or within one year after his military service and is not related to any incident in service.

The Board has determined that the veteran does not have any current disabilities related to his service, and therefore denied all of his claims for service connection.

The veteran's death was due to metastatic colon carcinoma, and the appellant is seeking service connection for his cause of death based on prostate cancer linked to herbicide exposure in Vietnam. The appeal is remanded to obtain additional medical records and determine if the veteran served in Vietnam.

The Board found no evidence of service connection for prostate cancer, melanoma, or eye blistering due to exposure to ionizing radiation, herbicides, or asbestos. The veteran's claims were denied.

The Board denied the veteran's claims for higher initial ratings for residuals of prostate cancer and impotence with bilateral testicular atrophy, finding that the evidence did not support a higher rating than what was already assigned.

The Board has determined that service connection is not warranted for prostate cancer or PTSD. Consequently, no disability rating or effective date will be assigned.

The Board's decision denying service connection for a skin disorder and prostate cancer was dismissed due to the Court's vacating and remanding of the decision.

The Board denied the veteran's claims for an initial rating higher than 40 percent for residuals of prostate cancer and a compensable rating for bilateral hearing loss.

The veteran's claims for service connection and increased evaluations were granted, with prostate cancer being presumed due to herbicide exposure. The eye disorder claim was denied, but the veteran is entitled to an increased evaluation for peripheral neuropathy in both lower extremities and a higher rating for diabetes mellitus.

The veteran is entitled to additional compensation for his spouse, S.J.H., due to the presence of at least one service-connected disability rated at 30% or more.

The Board found that the veteran's prostate cancer is not due to radiation exposure during service and denied his claim for service connection.

The Board granted separate 10 percent ratings for osteoarthritis of the right and left hip, a 20 percent rating for degenerative arthritis of the cervical spine, and 30 percent rating for duodenal ulcer, hiatal hernia and erosive esophagitis effective from October 25, 1999.

The Board denied the veteran's claims for increased ratings for PTSD and prostate cancer, finding that the evidence did not meet the criteria for higher ratings under the applicable rating schedule.

The Board has decided to remand the case for further development, including a VA examination and additional evidence collection. The veteran's prostate cancer is being considered based on exposure to pesticides during service.

The veteran is service connected for prostate cancer, rated as 60 percent disabling. The RO has granted a TDIU based on this disability. However, the issue of service connection for degenerative disc disease of the lumbar spine remains pending and must be remanded.

The Board has determined that the veteran's prostate cancer, which was diagnosed in 2002, is not service-connected as it did not occur during or within one year after his military service. The appeal for service connection for post-operative residuals of prostate cancer is denied.

The Board denied the veteran's claims for service connection for PTSD and prostate cancer with metastasis to the right humerus, finding no evidence of a verified in-service stressor or radiation exposure. The veteran was not granted any benefits.

The Board has granted a 20 percent disability rating for the residuals of prostate cancer, effective March 2005. A separate 10 percent rating is also granted for impairment of sphincter control (residuals of radiation treatment for prostate cancer).

The Board has remanded the case for further development to determine the current severity of the residuals of prostate cancer and whether it should be rated at 10%.